Print Page  Close Window

Corporate Profile

Paratek is developing and commercializing innovative antibacterial therapeutics based upon tetracycline chemistry. Paratek has used its expertise in microbial biology and tetracycline chemistry to create chemically diverse and biologically distinct small molecules derived from the tetracycline class of molecules. Paratek’s two lead antibacterial product candidates are omadacycline and sarecycline. Omadacycline entered Phase 3 clinical development in June 2015. Sarecycline entered Phase 3 clinical development in December 2014.

Stock Information

PRTK (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Up 0.28 (1.69%)
Data as of 01/22/18 4:00 p.m. ET

Latest News

Paratek Announces Pricing of Public Offering of Common Stock
Paratek Announces Public Offering of Common Stock
Paratek Provides Update on Pipeline Progress
FDA Accepts New Drug Application for Seysara™ (Sarecycline) for the Treatment of Moderate to Severe Acne
See More >>
Data provided by Nasdaq. Minimum 15 minutes delayed.